Use of Natural Gums and Cellulose Derivatives in Production of Sustained Release Metoprolol Tablets

REFERENCES

• Altaf S. A., Yu K., Parasrampuria J., Friend D. R. Guar gum-based sustained release diltiazem. Pharm. Res. 1998; 15(8)1196–1201, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Altaf S. A., Wong D., Gebert M., Larrabee S., Yu K, Friend D. R. Drug release profiles of swellable hydrocolloid formulations: USP apparatus 2 versus apparatus 3, in vitro correlation. Pharm. Technol. 1998b; 22: 62–70, [CSA]
   Google Scholar
• Banakar U. V. Pharmaceautical Dissolution Testing, 1st ed. Marcel Dekker, New York 1992; 191–194
   Google Scholar
• Bhalla H. L., Sanzgiri Y. D. An improved controlled release tablet of salbutamol sulphate. Ind. J. Pharm. Sci. 1987; 49: 22–25, [CSA]
   Google Scholar
• Castro I. A., Tirapegui J., Benedicto M. L. Effects of diet supplementation with three soluble polysaccharides on serum lipid levels of hypercholesterolemic rats. Food Chem. 2003; 80: 323–330, [CROSSREF], [CSA]
   Web of Science ®Google Scholar
• Catellani P. L., Vaona C., Plazzi P., Colombo P. Compressed matrices, formulation and drug release kinetics. Acta Pharm.Tech. 1988; 34(1)38–41, [CSA]
   Web of Science ®Google Scholar
• Chueh H. R., Zia H., Rhodes C. T. Optimization of sotalol floating and bioadhesive extended release tablet formulations. Drug Dev. Ind. Pharm. 1995; 21(15)1725–1747, [CSA]
   Web of Science ®Google Scholar
• Dürig T., Fassihi R. Guar-based monolithic matrix systems: effect of ionizable and non-ionizable substances and excipients on gel dynamics and release kinetics. J. Control. Rel. 2002; 80(1–3)45–56, [CSA]
   PubMed Web of Science ®Google Scholar
• FDA Guidance for industry. Dissolution Testing of immediate and Modified Release Solid Oral Dosage Forms. U.S. Department of Health and Human Services, Food and Drug Administration, Washingten, DC August, 1997; 32
   Google Scholar
• Friend D. R., Altaf S. A., Yu K., Gerbert M. Development of a zero-order nifedipine dosage form using COSRx technology. Proc. Int. Symp. Control. Rel. Bioact. Mater. 1997; 24: 311–312, [CSA]
   Google Scholar
• Gohel M. C., Panchal M. K. Novel use of similarity factors f2 and Sd for the development of diltiazem HCl modified-release tablets using a 3(2) factorial design. Drug Dev. Ind. Pharm 2002; 28(1)77–87, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Hogan J. E. Hydroxypropylmethylcellulose sustained release technology. Drug Dev. Ind. Pharm. 1989; 15: 975–999, [CSA]
   Web of Science ®Google Scholar
• Juarez H., Rico G., Villafuerte L. Influence of admixed carboxymethylcellulose on release of 4-aminopyridine from hydroxypropyl methylcellulose matrix tablets. Int. J. Pharm. 2001; 216(1–2)115–125, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMedGoogle Scholar
• Khullar P., Khar R. K., Agarwal S. P. Evaluation of guar gum in the preparation of sustained-release matrix tablets. Drug Dev. Ind. Pharm. 1998; 24(11)1095–1099, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• Krishnaiah Y. S., Karthikeyan R. S., Gouri S. V., Satyanarayana V. Three-layer guar gum matrix tablet formulations for oral controlled delivery of highly soluble trimetazidine dihydrochloride. J. Control. Rel. 2002; 81(1–2)45–56, [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Munday D. L., Cox P. G. Compressed xanthan and karaya gum matrices: hydration, erosion and drug release mechanisms. Int. J. Pharm. 2000; 203: 179–192, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Rao K. V.R., Devi K. P., Buri P. Cellulose matrices for zero-order release of soluble drugs. Drug Dev. Ind. Pharm. 1988; 14(15–17)2299–2320, [CSA]
   Web of Science ®Google Scholar
• Rao V. M., Haslam J. L., Stella V. J. Controlled and complete release of a model poorly water-soluble drug, prednisolone, from hydroxypropyl methylcellulose matrix tablets using (SBE) (7m)-beta-cyclodextrin as a solubilizing agent. J. Pharm. Sci. 2001; 90(7)807–816, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Ritger P. L., Peppas N. A. A simple equation for description of solute release. I. Fickian and non-Fickian release from non-swellable devices in the form of slabs, sphere, cylinders or discs. J. Control. Rel. 1987a; 59: 23–36, [CROSSREF], [CSA]
   Google Scholar
• Ritger P. L., Peppas N. A. A simple equation for description of solute release. II. Fickian and anomalous release from swellable devices. J. Control. Rel. 1987b; 5: 37–42, [CROSSREF], [CSA]
   Google Scholar
• Sinha V. R., Mittal B. R., Bhutani K. K., Kumria R. Colonic drug delivery of 5-flurouracil: an in vitro evaluation. Int. J. Pharm. 2004; 269: 101–108, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Sujja-areevath J., Munday D. L., Cox P. J., Khan K. A. Relationship between swelling, erosion and drug release from hydrophilic natural gum mini-matrix formulations. Eur. J. Pharm. Sci. 1998; 6: 207–217, [PUBMED], [INFOTRIEVE], [CROSSREF], [CSA]
   PubMed Web of Science ®Google Scholar
• Talukdar M. M., Michoel A., Rombaut P., Kinget R. Comparative study on xanthan gum and hydroxypropylmethylcellulose as matrices for controlled-release drug delivery. I. Compaction and in vitro drug release behavior. Int. J. Pharm. 1996; 129: 233–241, [CROSSREF], [CSA]
   Web of Science ®Google Scholar
• Talukdar M. M., Rombaut P., Kinget R. The release mechanism of an oral controlled-release delivery system for indomethacin. Pharm. Dev.Technol. 1998; 3(1)1–6, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar
• USP 25 USP/NF. United States Pharmacopeia/National Formulary (USP25/NF20). United States Pharmacopeial Convention, New York 2002; 1142–1142
   Google Scholar
• Yu K., Altaf S. A., Parasramuria J., Friend D. R. Sustained release ketoprofen: formulation development. Proc. Int. Symp. Control. Rel. Bioact. Mater. 1997; 24: 16–17, [CSA]
   Google Scholar
• Yu K., Gerbert M., Altaf S. A., Wong D, Friend D. R. Optimization of sustained release diltiazem formulations in man by use of an in vitro/in vivo correlation. J. Pharm. Pharmacol. 1998; 50: 845–850, [PUBMED], [INFOTRIEVE], [CSA]
   PubMed Web of Science ®Google Scholar